老年8项评估与老年弥漫性大B细胞淋巴瘤治疗强度及预后的关联
该回顾性多中心研究纳入451例≥65岁弥漫性大B细胞淋巴瘤患者,其中388例接受标准方案,评估老年8项评估(G8)对治疗分层和总生存(OS)的影响。研究提示高G8评分患者标准方案tARDI上限宜≥80%,低G8评分患者宜60%,但无论G8评分如何均应给予标准方案以改善OS。
要点
- G8与死亡风险呈线性关联,评分越高死亡风险越低。
- 高G8评分者标准方案tARDI上限宜≥80%,低G8评分者宜60%。
核心结论
- G8对老年DLBCL患者的OS有显著影响,可作为治疗分层参考工具。
- 标准方案tARDI上限在高G8评分患者宜≥80%,低G8评分患者宜60%,但标准方案应给予所有患者以改善OS。
研究设计与样本
- 回顾性多中心分析,纳入2007至2017年诊断的451例≥65岁DLBCL患者,其中388例接受标准方案。
- 主要终点为OS,总平均相对剂量强度(tARDI)定义为所有周期平均实际剂量强度除以计划剂量强度。
主要发现
- 限制性立方样条Cox模型显示G8与死亡风险呈线性关联。
关键数值与推荐
- 高G8评分患者标准方案tARDI上限宜≥80%。
- 低G8评分患者标准方案tARDI上限宜60%。
- 标准方案应给予所有患者,无论G8评分。
临床怎么用
- 可用G8评估老年DLBCL患者,辅助判断治疗强度与预后。
- 对高G8评分患者可考虑维持较高tARDI(≥80%),低G8评分患者可考虑60%。
- 不应因G8评分低而放弃标准方案治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Because of the heterogeneity among older patients with diffuse large B-cell lymphoma (DLBCL), the establishment of an easy-to-use geriatric assessment tool is an unmet need. We verified the impact of the Geriatric 8 (G8) on treatment stratification and overall survival (OS). We conducted a retrospective, multicentre analysis of older patients (≥65 years) with DLBCL. The primary endpoint was OS. The total average relative dose intensity (tARDI) was defined as the average delivered dose intensity divided by the planned dose intensity through all cycles. A total of 451 patients were diagnosed with DLBCL from 2007 to 2017, and 388 patients received standard regimens. A multivariate Cox model confirmed that the G8 was a significant predictor of OS (hazard ratio 0·88, 95% confidence interval 0·828-0·935). A Cox model with restricted cubic spline showed a linear association between the G8 and the mortality risk. The G8 had a significant impact on OS in elderly patients with DLBCL. The upper limit of tARDI for standard regimens to improve OS might be appropriate at ≥80% for patients with high G8 scores and 60% for patients with low G8 scores. However, the standard regimens should be given to all patients regardless of the G8 score to improve OS.
引用
- Lee S, Fujita K, Morishita T, et al. Association of the Geriatric 8 with treatment intensity and prognosis in older patients with diffuse large B-cell lymphoma. Br J Haematol. 2021. PMID: 34041751. doi:10.1111/bjh.17554
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。